Seaport Therapeutics, Inc. SPTX
21.50 USD +1.11 (+5.44%)
At closeNov 6, 2026, 4:00 PM EST
21.50 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
19.77 Day range 21.75
14.85 52-week range 28.38
- YTD
- +8.37%
- 1 year
- +8.37%
News
benzinga.com JP Morgan Maintains Overweight on Seaport Therapeutics, Raises Price Target to $41 JP Morgan analyst Tessa Romero maintains Seaport Therapeutics (NASDAQ:SPTX) with a Overweight and raises the price target from $40 to $41.
zacks.com How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91% The mean of analysts' price targets for Seaport Therapeutics, Inc (SPTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
benzinga.com Seaport Therapeutics Q3 EPS $(0.49) Beats $(0.58) Estimate Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.58) by 15.52 percent. This is a 94.8 percent increase over losses of…
businesswire.com Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
benzinga.com This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
benzinga.com Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28 Canaccord Genuity analyst Sumant Kulkarni initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $28.
benzinga.com Seaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13 Congress is taking place October 10-13, 2026, in Munich, Germany. The poster represents the first scientific presentation of data from the GlyphAgo Phase 1 program and provides detailed…